Cytokinetics Inc
CYTKFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Cytokinetics Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 27 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 29, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Cytokinetics Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-06-24 · Lee Sung: Larger than 74 of the 75 other insider sales of Common Stock on file. SEC filing
- 2026-05-05 · HENDERSON JOHN T: Larger than 69 of the 75 other insider sales of Common Stock on file. SEC filing
- 2026-05-05 · Lee Sung: Larger than 71 of the 75 other insider sales of Common Stock on file. SEC filing
- 2026-05-01 · Callos Andrew: Larger than 68 of the 75 other insider sales of Common Stock on file. SEC filing
- 2026-03-17 · Blum Robert I: Larger than 72 of the 75 other insider sales of Common Stock on file. SEC filing
- 2025-12-22 · WIERENGA WENDELL: Larger than 69 of the 75 other insider sales of Common Stock on file. SEC filing
- 2025-12-05 · Callos Andrew: Larger than all 75 other insider sales of Common Stock on file. SEC filing
- 2025-12-01 · Kaye Edward M. MD: Larger than 73 of the 75 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Common Stock | S — Open market or private sale | −3,134 | 85.00 | SEC filing |
| 2026-06-24 | Lee Sung · EVP, Chief Financial Officer | Common Stock | S — Open market or private sale | −38,730 | 82.30 | SEC filing |
| 2026-06-23 | Malik Fady Ibraham · EVP Research & Development | Common Stock | S — Open market or private sale | −3,500 | 79.51 | SEC filing |
| 2026-06-15 | Blum Robert I · President & CEO | Common Stock | S — Open market or private sale | −7,500 | 70.46 | SEC filing |
| 2026-06-09 | Malik Fady Ibraham · EVP Research & Development | Common Stock | S — Open market or private sale | −3,500 | 67.98 | SEC filing |
| 2026-06-01 | Callos Andrew · EVP, Chief Commercial Officer | Common Stock | S — Open market or private sale | −15,000 | 74.08 | SEC filing |
| 2026-06-01 | Kaye Edward M. MD · Director | Common Stock | S — Open market or private sale | −2,933 | 76.09 | SEC filing |
| 2026-06-01 | PARSHALL B LYNNE · Director | Common Stock | S — Open market or private sale | −5,000 | 74.08 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Non-Qualified Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −823 | SEC filing |
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +188 | SEC filing |
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +1,113 | SEC filing |
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Non-Qualified Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −1,113 | SEC filing |
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Incentive Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −188 | SEC filing |
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +823 | SEC filing |
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +822 | SEC filing |
| 2026-06-29 | Lee Sung · EVP, Chief Financial Officer | Non-Qualified Stock Option (Right to Buy) | M — Exercise or conversion of derivative security | −822 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.